Conversion therapy with immunotherapy plus chemotherapy achieves a pathological complete response in stage IIIC NSCLC.

导出 LinkOut

翻译打印收藏纠错

第一作者： Yu,Fu

第一单位： Department of Thoracic Surgery, Shengjing Hospital of China Medical University, Shenyang, China.

作者： Yu,Fu ^[1] ; Weichen,Duan ^[2] ; Ran,Xu ^[1] ; Jiajia,Chen ^[2]

作者单位： Department of Thoracic Surgery, Shengjing Hospital of China Medical University, Shenyang, China. ^[1] Department of Oncology, Shengjing Hospital of China Medical University, Shenyang, China. ^[2]

关键词 chemotherapy histologic transformation immunotherapy neoadjuvant therapy non-small cell lung cancer

主题词人类(Humans);癌, 非小细胞肺(Carcinoma, Non-Small-Cell Lung);肺肿瘤(Lung Neoplasms);肿瘤分期(Neoplasm Staging);预后(Prognosis);免疫疗法(Immunotherapy)

DOI 10.3389/fimmu.2023.1268153

PMID 38022567

发布时间 2024-03-22

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

Frontiers in immunology

2023年14卷

1268153页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Conversion therapy with immunotherapy plus chemotherapy achieves a pathological complete response in stage IIIC NSCLC.

Frontiers in immunology

相似文献

Frontiers in immunology

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Conversion therapy with immunotherapy plus chemotherapy achieves a pathological complete response in stage IIIC NSCLC.

Frontiers in immunology

相似文献

Frontiers in immunology

相关期刊

检索历史清除